News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Access to medicines and treatment news

Show

From To
Changing treatment
Second-line NRTI-sparing regimen proves equally effective for resource-limited settings

A second-line antiretroviral regimen of lopinavir/ritonavir (Kaletra/Aluvia) and raltegravir (Isentress) proved just as effective as a regimen containing lopinavir/ritonavir and two or three nucleoside or nucleotide analogues

Published
07 March 2013
By
Keith Alcorn
Opportunistic infections
Continuing cotrimoxazole in children on ART reduces the risk of hospitalisation

Children on ART for more than two years who continued taking daily cotrimoxazole had significantly fewer hospitalisations for malaria as well as for non-malarial infections (notably pneumonia, sepsis

Published
06 March 2013
By
Carole Leach-Lemens
Health monitoring in resource-limited settings
HIV treatment for children is safe and highly effective without laboratory monitoring in large African trial

Children did just as well on antiretroviral therapy without routine laboratory monitoring of CD4 cell counts or drug side-effects as those who received regular monitoring during four

Published
05 March 2013
By
Keith Alcorn
Access to medicines and treatment
U.S. “Stalling” Could Force Acceptance of Onerous TPP

Civil society opposition here has strengthened against a U.S.-proposed free trade zone that would include some dozen countries around the Pacific Rim. As negotiators head into a 16th round of talks this week in Singapore, around 400 organisations are urging the U.S. Congress to demand greater transparency in the proceedings.

Published
05 March 2013
From
Inter Press Service
Access to medicines and treatment
India board rules against Bayer in cancer drug patent case

An Indian patent appeals board upheld on Monday a decision to allow a domestic company to sell a generic version of Bayer AG's cancer drug Nexavar, in a blow for global drugmakers' efforts to hold on to monopolies on high-price medicines.

Published
05 March 2013
From
Chicago Tribune
Finance and funding
US: Sequester could lead to massive cuts in HIV testing, treatment

The AIDS Drug Assistance Program is among the many federal programs that will take a hit if $85 billion in across-the-board spending cuts go through March 1, and those cuts could potentially lead to an increase in HIV transmission, the White House said Sunday in a report on the anticipated state-by-state impacts of the so-called sequester.

Published
04 March 2013
From
Salon
Health monitoring in resource-limited settings
Alere to Develop Simple, Affordable Point-of-Care Nucleic Acid Test for Tuberculosis & Expand Manufacturing for POC HIV Viral Load Platform

Alere Inc. announced that it has been awarded a grant of up to $21.6 million and debt financing of up to $20.6 million from the Bill & Melinda Gates Foundation to support development of a point-of-care nucleic acid test for tuberculosis and to expand production facilities for this test and for a point-of-care viral load test.

Published
02 March 2013
From
Alere
Access to medicines and treatment
India May Drop Compulsory Licenses Based On Price

India’s Department of Pharmaceuticals this week issued a new draft guidance that says once patented drugs come under proposed price controls, the cost of these medicines should be considered reasonable and compulsory license should not be issued based on affordability.

Published
02 March 2013
From
Pharmalot
Access to medicines and treatment
Detailed analysis of the Medicines Patent Pool-ViiV pediatric ARV license and memorandum of understanding

This License Agreement and its subsidiary Sublicense Agreement will be a presumptive template for pediatric access to all of ViiV's current pipeline ARVs once they are approved by for use by the US Food and Drug Administration (FDA) or by the European Medicines Authority (EMA).   On February 27, the Medicines Patent Pool (MPP) and ViiV Healthcare UK Limited (ViiV) announced their License Agreement on an older antiretroviral (ARV), abacavir (ABC), for pediatric treatment only, in 118 countries where 98.7% of child living with HIV live.  They also entered into a separate, non-binding Memorandum of Agreement (MoU),...

Published
01 March 2013
From
EATG
Finance and funding
HIV drugs to be uniquely shielded from generic pricing pressure in public payer scheme

HIV drug makers in the US are expected to be somewhat protected from generic drug pricing pressure given the emphasis on single-tablet regimens (STRs) and the large role of public payers, experts told BioPharm Insight. The role of private payers is more uncertain, they added.

Published
01 March 2013
From
Financial Times
← Prev12345...46Next →

Filter by country